Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Drops By 82.8%

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 8,200 shares, a drop of 82.8% from the February 29th total of 47,600 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 42,600 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of enGene

Several large investors have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in shares of enGene in the 4th quarter valued at about $185,000. Goldman Sachs Group Inc. acquired a new position in enGene during the 4th quarter valued at about $346,000. Royal Bank of Canada acquired a new position in enGene during the 4th quarter valued at about $349,000. Vivo Capital LLC acquired a new position in enGene during the 4th quarter valued at about $6,264,000. Finally, Omega Fund Management LLC acquired a new position in enGene during the 4th quarter valued at about $10,441,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Price Performance

Shares of ENGN traded down $0.29 during trading hours on Thursday, hitting $16.95. The stock had a trading volume of 34,993 shares, compared to its average volume of 45,045. The business’s 50 day moving average is $13.16. enGene has a 1-year low of $6.69 and a 1-year high of $43.00.

Analyst Ratings Changes

ENGN has been the subject of a number of recent analyst reports. Morgan Stanley initiated coverage on enGene in a report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target for the company. SVB Leerink initiated coverage on enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price target for the company. Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. Finally, UBS Group initiated coverage on enGene in a report on Thursday. They set a “buy” rating and a $37.00 price target for the company.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.